Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Kun Run Reports Strong 2008 Results

publication date: Apr 1, 2009

Kun Run Biotechnology, a company that focuses on peptide-based drugs, reported that 2008 revenues climbed 56% to $11.6 million. Net income nearly tripled from the year earlier, rising to $6 million or 52% of sales on a non-GAAP basis. Earnings per share were 24 cents, fully diluted. The $6 million net income number includes a $2.4 million extraordinary gain from the sale of property, and also reflects a one-time charge for a Make-Good Provision, which reduced earnings by $1.3 million. More details...

Stock Symbol: (OTCBB: KURU)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital